# A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy

> **NCT05853432** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 157 (actual)

## Conditions studied

- HR+/HER2- Advanced or Metastatic Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05853432
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-16
- **Primary completion:** 2022-05-02
- **Final completion:** 2022-05-02
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2023-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05853432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05853432, "A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05853432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*